Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Jabak and Najjari Discussed the Cooperation between Lebanon and Egypt in the Exchange of Medicines

 
Minister of Public Health Jamil Jabak received UN Special coordinator for Lebanon Philippe Lazzarini. Both discussed the collaboration between the Ministry of Public Health and all the UN organizations working in Lebanon, such as UNIFIL, UNRWA or UNESCO. Lazzarini reiterated the continuing support to the activities of the Ministry of Public Health and follow-up of the donor countries’ programs that are related to the health care sector, in addition to building a joint collaboration in development projects between Lebanon and the United Nations and working on the establishment of better relationships.
 
The Egypt ambassador Nazih Najjari visited also Minister Jabak and stressed the importance of the economic collaboration between the two countries, in particular in the field of medicines. Najjari hoped that Jabak would review the hospitalization systems related to the Egyptian community in Lebanon and whether it is possible to develop the systems while paying attention to the health conditions of the community.
 
Jabak also met with UNRWA Director General in Lebanon Claudio Cordone who presided over a delegation from the agency. “The meeting discussed the collaboration between both parties to ensure the access of Palestinians in Lebanon to health, medical and hospitalization services they need,” Cordone stated.
 
Jabak received a delegation from the board of pharmacists in Lebanon headed by Ghassan Al Amin. Both discussed the situation of health care sector in Lebanon, in particular the medicines dossier and the ways to reduce their costs. It was agreed to form a joint committee to discuss the means to achieve this goal.
 
Jabak then met with the ambassador of the Association of the Malta knights Henry D’Aragon accompanied by the chargé d’affaires François Abi Saab and the representative of the association at the Ministry Khaled Kaskas. D’Aragon stressed the Association’s commitment to preserve the best relationships with Lebanon, indicating readiness to develop and improve them.
    ...
    117
    ...
ATC Name B/G Ingredients Dosage Form Price
L01FA03 GAZYVA BioTech Obinutuzumab - 1000mg/40ml 1000mg/40ml Injectable concentrate for solution L.L
L01FA03 GAZYVA BioTech Obinutuzumab - 1000mg/40ml 1000mg/40ml Injectable concentrate for solution 314,437,416 L.L
L01FB01 BESPONSA FOR INJECTION BioTech Inotuzumab Ozogamicin - 0.9mg 0.9mg Injectable powder for suspension 921,176,511 L.L
L01FC01 DARZALEX BioTech Daratumumab - 400mg/20ml 400mg/20ml Injectable concentrate for solution L.L
L01FC01 DARZALEX BioTech Daratumumab - 400mg/20ml 400mg/20ml Injectable concentrate for solution 164,970,376 L.L
L01FC01 DARZALEX BioTech Daratumumab - 1800mg 1800mg Injectable solution 494,909,963 L.L
L01FD01 TRASTUREL BioTech Trastuzumab - 440mg L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 440mg 440mg Injectable powder for concentrate for solution + solvent 34,948,930 L.L
L01FD01 HERCEPTIN BioTech Trastuzumab - 440mg 21mg/ml Injectable concentrated powder for solution+diluent 166,423,476 L.L
L01FD01 HERCEPTIN BioTech Trastuzumab - 440mg 21mg/ml Injectable concentrated powder for solution+diluent 166,423,476 L.L
L01FD01 HERZUMA BioTech Trastuzumab - 440mg 440mg Injectable powder for concentrate for solution 89,046,707 L.L
L01FD01 MABTIN 440 BioTech Trastuzumab (r-DNA origin) - 440mg 440mg Injectable powder for solution 70,042,700 L.L
L01FD01 OGIVRI BioTech Trastuzumab - 440mg 440mg Injectable lyophilised powder 80,027,615 L.L
L01FD01 TRASTUREL BioTech Trastuzumab - 440mg 440mg Injectable lyophilised powder 52,047,114 L.L
L01FD01 TRAZIMERA BioTech Trastuzumab - 440mg 440mg Injectable powder for solution+solvent 75,295,202 L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 150mg 150mg Injectable powder for concentrate for solution 21,176,745 L.L
L01FD01 HERZUMA BioTech Trastuzumab - 150mg 150mg Injectable powder for concentrate for solution 36,062,671 L.L
L01FD01 TRAZIMERA BioTech Trastuzumab - 150mg 150mg Injectable powder for solution 28,550,630 L.L
L01FD01 KANJINTI BioTech Trastuzumab - 420mg 420mg Injectable powder for concentrate for solution 79,305,881 L.L
L01FD02 PERJETA 420MG BioTech Pertuzumab - 420mg/14ml 420mg/14ml Injectable concentrate for solution L.L
L01FD02 PERJETA 420MG BioTech Pertuzumab - 420mg/14ml 420mg/14ml Injectable concentrate for solution 220,054,714 L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 100mg 100mg Injectable powder for concentrate for solution L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 160mg 160mg Injectable powder for concentrate for solution L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 100mg 100mg Injectable powder for concentrate for solution 135,545,977 L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 160mg 160mg Injectable powder for concentrate for solution 216,872,714 L.L
L01FD04 ENHERTU BioTech Trastuzumab deruxtecan - 100mg 100mg Injectable powder for concentrate for solution 178,517,964 L.L
L01FE01 ERBITUX BioTech Cetuximab - 100mg/20ml 100mg/20ml Injectable solution L.L
L01FE01 ERBITUX BioTech Cetuximab - 100mg/20ml 100mg/20ml Injectable solution 24,001,769 L.L
L01FE02 VECTIBIX BioTech Panitumumab - 400mg/20ml 400mg/20ml Injectable concentrated solution L.L
L01FE02 VECTIBIX BioTech Panitumumab - 100mg/5ml 100mg/5ml Injectable concentrated solution L.L
    ...
    117
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025